Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19 - Redondo-Calvo, F J; Padin, J F; Munoz-Rodriguez, J R (Eur J Clin Invest, 2022)
et al.